Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use.

ABSTRACT:

Background

Chemotherapy-induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized study, romiplostim led to correction of platelet counts in 85% of treated patients and allowed resumption of chemotherapy, with low rates of recurrent CIT in the first two cycles or 8 weeks of chemotherapy. However, there is a lack of long-term data on the efficacy and safety of romiplostim in CIT.

Objectives

To analyze efficacy and safety of romiplostim in the patients in the phase 2 study, who received romiplostim for ≥1 year.

Patients/methods

Twenty-one patients remained on romiplostim for ≥1 year. We analyzed the effect of romiplo

SUBMITTER: Wilkins CR 

PROVIDER: S-EPMC9087952 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature